Vanguard Group Inc In8 Bio, Inc. Transaction History

Vanguard Group Inc

$5.37 Trillion
Q1 2025

A detailed history of Vanguard Group Inc transactions in In8 Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,802,956 shares of INAB stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,802,956

Previous 1,423,897 26.62%

Holding current value

$3.93 Million

Previous $384,000 20.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$0.17 - $0.35 $64,440 - $132,670	379,059 Added 26.62%	1,802,956 $306,000
Q1 2024 May 10, 2024	BUY	$0.95 - $1.69 $956,840 - $1.7 Million	1,007,201 Added 241.71%	1,423,897 $1.68 Million
Q4 2023 Feb 14, 2024	BUY	$0.69 - $2.34 $53,797 - $182,445	77,968 Added 23.02%	416,696 $575,000
Q3 2023 Nov 14, 2023	BUY	$0.92 - $1.74 $47,068 - $89,020	51,161 Added 17.79%	338,728 $352,000
Q2 2023 Aug 14, 2023	BUY	$1.05 - $3.24 $81,371 - $251,090	77,497 Added 36.89%	287,567 $442,000
Q1 2023 May 15, 2023	BUY	$1.17 - $2.83 $48,454 - $117,201	41,414 Added 24.56%	210,070 $273,000
Q4 2022 Feb 10, 2023	SELL	$1.39 - $2.47 $1,212 - $2,153	-872 Reduced 0.51%	168,656 $389,000
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.89 $104,134 - $170,027	58,833 Added 53.15%	169,528 $342,000
Q2 2022 Aug 12, 2022	SELL	$2.02 - $4.68 $1,611 - $3,734	-798 Reduced 0.72%	110,695 $250,000
Q1 2022 May 13, 2022	SELL	$2.76 - $4.6 $24,075 - $40,125	-8,723 Reduced 7.26%	111,493 $372,000
Q4 2021 Feb 14, 2022	BUY	$4.39 - $8.55 $31,239 - $60,841	7,116 Added 6.29%	120,216 $528,000
Q3 2021 Nov 12, 2021	BUY	$6.71 - $10.0 $758,901 - $1.13 Million	113,100 New	113,100 $775,000

Others Institutions Holding INAB

# of Institutions

Shares Held

21.7M

Call Options Held

Put Options Held

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $53.4M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc In8 Bio, Inc. Transaction History